Top Tweets for #GoodDoctors

Good point! But we must also keep in mind that these neurological manifestations—autonomic dysfunction, ganglionopathies, CIDP-like features, trigeminal neuropathy, cognitive issues—can also be seen in other autoimmune diseases like SLE, sarcoidosis, systemic sclerosis, vasculitis (e.g., PAN), mixed connective tissue disease, and even in paraneoplastic, infectious, or metabolic conditions. So while their presence increases the suspicion for Sjögren’s, they are not specific—and diagnosis must be made in a broader clinical-serological-radiological context. Also, anti-Ro52 positivity is not exclusive to Sjögren’s. It is seen in 15–20% of patients with myositis, systemic sclerosis, and even some infections or malignancies [1,2]. So, a positive Ro52 alone should not label someone as having Sjögren’s. Interestingly, up to 40–60% of Neuro-Sjögren’s patients may lack classical sicca features, and present solely with myelitis, sensory ganglionopathy, or autonomic neuropathy. So both overdiagnosis and underdiagnosis are possible—hence, clinical judgment and pattern recognition remain key. Let’s always interpret the patient's full story—clinical symptoms, serology, imaging, and evolution over time—before anchoring to a single label.